Jazz Pharma could shift EU roles from Oxford to Ireland
Jazz Pharmaceuticals could shift EU-specific roles currently based in Oxford to its Dublin world headquarters in the event of a no-deal Brexit.
The company's chairman and chief executive, Bruce Cozadd, said some of the 150 Jazz jobs currently based in England would have to be switched to a European Union base if the UK leaves.
He said the Oxford base would continue to grow in size regardless of Brexit, in part because of local expertise and the size of the UK's own market, but key regulatory and quality-control staff qualified in the EU's pharmacovigilance system would have to move. Such workers handle risk management, and the assessment, understanding and communication of safety information.
When asked if Ireland was a likely post-Brexit destination for EU regulatory roles currently filled in Oxford, Mr Cozadd responded with a "yes".
"Some functions must be performed in Europe. In some cases, we've had people in Oxford performing those functions. If the UK is no longer part of Europe, we will need to move those functions elsewhere, where we do product testing," he said. "These issues are being faced by all pharma companies."
He was speaking to the Irish Independent ahead of the company's Dublin AGM today.